Picsure Competitors

Solis Mammography is a specialized healthcare provider that has been dedicated to helping women achieve and maintain breast health for 40 years. With breast-dedicated radiologists, state-of-the art technology, and a woman-centric, high-touch experience, Solis Mammography pioneered the Home of the Peace of Mind Mammogram™. As the nation’s largest independent provider of breast screening and diagnostic services, the company operates both wholly owned centers and multiple successful joint venture partnerships with large hospital systems, physician practices and prominent medical and academic institutions. Headquartered in Addison, Texas, Solis Mammography operates more than 150 centers in 20 major markets.

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.

Lunit is a leading provider of AI solutions for cancer diagnostics and therapeutics, with a mission to conquer cancer through AI. Our clinically proven AI enables healthcare providers to detect cancer earlier, make more precise treatment decisions, and improve patient outcomes — transforming how cancer is diagnosed and treated. Our technology spans the entire cancer continuum, from risk prediction and screening optimization to early detection and precision oncology. Lunit’s breast and chest imaging AI boosts diagnostic accuracy and efficiency, while our pathology AI is leveraged by leading pharmaceutical companies to drive biomarker discovery and companion diagnostics (CDx) development. Trusted by 10,000+ sites across 65+ countries, Lunit continues to redefine global standards in data-driven cancer care. Learn more about our technology and mission at www.lunit.io/en